Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul>
<li>The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.</li>
<li>This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.</li>
<li>Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. </li>
</ul>


The clinical stage biotech company has received its first milestone royalty payment of $0.5m from Ligand Pharmaceuticals Incorporated.
This is in relation to AT220, an Arestat-enhanced biosimilar product and under the terms of the Agreement, the first commercial milestone has been achieved, resulting in a $0.5m payment to Arecor.
Arecor expects to receive a further $0.5m in the H2 2026 and the remaining $3m is contingent upon achievement of future commercial milestones which remain on track. 


ハイブリダン小型株の祭典：2026年3月26日

Nanoco Group PLC

ハイブリダン小型株の祭典：2026年3月26日